Treatment with an HSP90 inhibitor (PU-H71 or 17-AAG) and a combination of CDK9 inhibitors (AZD4573) induced impressive anti-MCL activity both in vitro and in vivo the MCL-PDX model [187]. This evidence concerns the gene CDK9 and mantle cell lymphoma.